Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Synthesis, in Vitro Potency of Inhibition, Enzyme Kinetics and in Silico Studies of Quinoline-Based Α-Glucosidase Inhibitors Publisher Pubmed

Summary: Can quinoline hybrids manage diabetes? A study found these compounds effectively inhibit α-glucosidase, suggesting new type 2 diabetes treatments. #DiabetesResearch #DrugDiscovery

Ghomi MK1 ; Dastyafteh N1 ; Montazer MN1 ; Noori M1 ; Mojtabavi S2 ; Faramarzi MA2 ; Hashemi SM3 ; Mahdavi M1
Authors

Source: Scientific Reports Published:2024


Abstract

Diabetes mellitus is a multifactorial global health disorder that is rising at an alarming rate. One effective therapeutic approach for controlling hyperglycemia associated with type-2 diabetes is to target α-glucosidase, which catalyzes starch hydrolysis in the intestine. In an attempt to find potential α-glucosidase inhibitors, a series of twenty new quinoline linked benzothiazole hybrids (8a–t) were synthesized in good yields from suitable reaction procedures and their chemical structures were analyzed by 1HNMR, 13CNMR, IR, and ESI–MS analysis. The synthesized derivatives further screened for their activity against α-glucosidase. Among them, compounds 8b, 8h, 8n and 8o exhibited remarkable α-glucosidase inhibitory activity with IC50 values ranging from 38.2 ± 0.3 to 79.9 ± 1.2 µM compared with standard drug acarbose (IC50 = 750.0 ± 2.0 µM). Enzyme kinetic studies of the most active compound (8h) indicated a non-competitive inhibition with Ki value of 38.2 µM. Moreover, the homology modeling, molecular docking and molecular dynamics simulation studies were conducted to reveal key interactions between the most active compound 8h and the targeted enzyme. These results are complementary to the experimental observations. In order to predict the druggability of the novel derivatives, the pharmacokinetic properties were also applied. These findings could be useful for the design and development of new α-glucosidase inhibitors. © 2024, The Author(s).
Other Related Docs